Neue Ansätze zur Früherkennung von Vorhofflimmern

ZUSAMMENFASSUNG

Vorhofflimmern (VHF) ist mit dem Auftreten von ischämischen Schlaganfällen assoziiert. Orale Antikoagulation kann das Auftreten von Schlaganfällen verhindern. Das Screening auf ein bislang nicht entdecktes VHF erscheint daher ein vielversprechender Ansatz, um das Auftreten von Schlaganfällen zu verhindern. Neben zahlreichen anderen wissenschaftlichen Studien liegen seit August 2021 die Ergebnisse von 2 Studien mit klinischen Endpunkten vor, die STROKESTOP- und die LOOP-Studie. Weitere wissenschaftliche Untersuchungen zu dieser Fragestellung befinden sich in der Durchführung.

ABSTRACT

Atrial fibrillation is associated with the occurrence of ischemic stroke. Oral anticoagulation may prevent strokes. Screening for previously undetected AF therefore appears to be a promising approach to prevent strokes. Among numerous other scientific studies, the results of 2 trials with clinical endpoints, the STROKESTOP and LOOP trials, have been available since August 2021. They provide first evidence that atrial fibrillation screening may be efficient. Further scientific studies regarding this issue are ongoing.

Schlüsselwörter

Vorhofflimmern - Screening - Prävention - Schlaganfall - randomisierte Studie - Wearables

Key words

Atrial fibrillation - screening - prevention - stroke - randomised study - wearables

• Literatur

• 1 Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol 2014; 11: 639-654
• 2 Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke 2021; 16: 217-221
• 3 Chugh SS, Havmoeller R, Narayanan K. et al Worldwide Epidemiology of Atrial Fibrillation: A Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-847
• 4 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988
• 5 Jørgensen HS, Nakayama H, Reith J. et al Acute Stroke With Atrial Fibrillation. Stroke 1996; 27: 1765-1769
• 6 Kimura K. Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005; 76: 679-683
• 7 Marini C, De Santis F, Sacco S. et al Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke: Results From a Population-Based Study. Stroke 2005; 36: 1115-1119
• 8 Leyden JM, Kleinig TJ, Newbury J. et al Adelaide Stroke Incidence Study. Stroke 2013; 44: 1226-1231
• 9 Friberg L, Rosenqvist M, Lindgren A. et al High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke. Stroke 2014; 45: 2599-2605
• 10 Yiin GSC, Howard DPJ, Paul NLM. et al Age-Specific Incidence, Outcome, Cost, and Projected Future Burden of Atrial Fibrillation – Related Embolic Vascular Events. Circulation 2014; 130: 1236-1244
• 11 Palm F, Kleemann T, Dos Santos M. et al Stroke due to atrial fibrillation in a population-based stroke registry (Ludwigshafen Stroke Study) CHADS2, CHA2DS2-VASc score, underuse of oral anticoagulation, and implications for preventive measures. Eur J Neurol 2013; 20: 117-123
• 12 Gladstone DJ, Spring M, Dorian P. et al Atrial Fibrillation in Patients with Cryptogenic Stroke. N Engl J Med 2014; 370: 2467-2477
• 13 Sanna T, Diener H-C, Passman RS. et al Cryptogenic Stroke and Underlying Atrial Fibrillation. N Engl J Med 2014; 370: 2478-2486
• 14 Rubio Campal JM, García Torres MA, Sánchez Borque P. et al Detecting Atrial Fibrillation in Patients With an Embolic Stroke of Undetermined Source (from the DAF-ESUS registry). Am J Cardiol 2020; 125: 409-414
• 15 Flint AC, Banki NM, Ren X. et al Detection of Paroxysmal Atrial Fibrillation by 30-Day Event Monitoring in Cryptogenic Ischemic Stroke. Stroke 2012; 43: 2788-2790
• 16 Melis F, Guido M, Amellone C. et al Prevalence and predictors of atrial fibrillation in patients with embolic stroke of undetermined source: a real-life single-center retrospective study. Neurol Sci 2021; 42: 3707-3714
• 17 Ziegler PD, Rogers JD, Ferreira SW. et al Long-term detection of atrial fibrillation with insertable cardiac monitors in a real-world cryptogenic stroke population. Int J Cardiol 2017; 244: 175-179
• 18 Diener H-C, Sacco RL, Easton JD. et al Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med 2019; 380: 1906-1917
• 19 Hart RG, Sharma M, Mundl H. et al Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. N Engl J Med 2018; 378: 2191-2201
• 20 Hindricks G, Potpara T, Dagres N. et al 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2021; 42: 373-498
• 21 Gage BF, van Walraven C, Pearce L. et al Selecting Patients With Atrial Fibrillation for Anticoagulation. Circulation 2004; 110: 2287-2292
• 22 Olesen JB, Lip GYH, Hansen ML. et al Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124
• 23 Lip GYH, Nieuwlaat R, Pisters R. et al Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based Approach: The Euro Heart Survey on Atrial Fibrillation. CHEST 2010; 137: 263-272
• 24 Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33: 1500-1510
• 25 Pisters R, Lane DA, Nieuwlaat R. et al A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation: The Euro Heart Survey. CHEST 2010; 138: 1093-1100
• 26 Hohnloser SH, Basic E, Hohmann C. et al Effectiveness and Safety of Non–Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation. Thromb Haemost 2018; 118: 526-538
• 27 Bergmann MW. LAA occluder device for stroke prevention: Data on WATCHMAN and other LAA occluders. Trends Cardiovasc Med 2017; 27: 435-446
• 28 Holmes DR, Kar S, Price MJ. et al Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy. J Am Coll Cardiol 2014; 64: 1-12
• 29 Chen S, Chun KRJ, Bordignon S. et al Left atrial appendage occlusion using LAmbre Amulet and Watchman in atrial fibrillation. J Cardiol 2019; 73: 299-306
• 30 López-López JA, Sterne JAC, Thom HHZ. et al Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359: j5058
• 31 Connolly SJ, Ezekowitz MD, Yusuf S. et al Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151
• 32 Granger CB, Alexander JH, McMurray JJV. et al Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-992
• 33 Patel MR, Mahaffey KW, Garg J. et al Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med 2011; 365: 883-891
• 34 Giugliano RP, Ruff CT, Braunwald E. et al Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2013; 369: 2093-2104
• 35 Schwabe U, Ludwig W-D. Hrsg Arzneiverordnungs-Report 2020. Heidelberg: Springer; 2020
• 36 Son Y-J, Baek K-H, Lee SJ. et al Health-Related Quality of Life and Associated Factors in Patients with Atrial Fibrillation: An Integrative Literature Review. Int J Environ Res Public Health 2019: 16
• 37 Witassek F, Springer A, Adam L. et al Health-related quality of life in patients with atrial fibrillation: The role of symptoms, comorbidities, and the type of atrial fibrillation. PLOS ONE 2019; 14: e0226730
• 38 Boriani G, Laroche C, Diemberger I. et al Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry. Am J Med 2015; 128: 509-518.e2
• 39 Flaker GC, Belew K, Beckman K. et al Asymptomatic atrial fibrillation: Demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005; 149: 657-663
• 40 Borowsky LH, Regan S, Chang Y. et al First Diagnosis of Atrial Fibrillation at the Time of Stroke. Cerebrovasc Dis 2017; 43: 192-199
• 41 Sposato LA, Cipriano LE, Saposnik G. et al Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2015; 14: 377-387
• 42 Gorenek B, Pelliccia A, Benjamin EJ. et al European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS). Eur J Prev Cardiol 2017; 24: 4-40
• 43 Kaleschke G, Hoffmann B, Drewitz I. et al Prospective, multicentre validation of a simple, patient-operated electrocardiographic system for the detection of arrhythmias and electrocardiographic changes. Europace 2009; 11: 1362-1368
• 44 Healey JS, Israel CW, Capucci A. et al Subclinical Atrial Fibrillation and the Risk of Stroke. N Engl J Med 2012: 10
• 45 Healey JS, Alings M, Ha A. et al Subclinical Atrial Fibrillation in Older Patients. Circulation 2017; 136: 1276-1283
• 46 Brambatti M, Connolly SJ, Gold MR. et al Temporal Relationship Between Subclinical Atrial Fibrillation and Embolic Events. Circulation 2014; 129: 2094-2099
• 47 Bertaglia E, Blank B, Blomström-Lundqvist C. et al Atrial high-rate episodes: prevalence, stroke risk, implications for management, and clinical gaps in evidence. EP Eur 2019; 21: 1459-1467
• 48 Svennberg E, Friberg L, Frykman V. et al Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. The Lancet 2021; 398: 1498-1506
• 49 Svendsen JH, Diederichsen SZ, Højberg S. et al Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. The Lancet 2021; 398: 1507-1516
• 50 Camm AJ, Simantirakis E, Goette A. et al Atrial high-rate episodes and stroke prevention. EP Eur 2017; 19: 169-179
• 51 Goette A, Kalman JM, Aguinaga L. et al EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. EP Eur 2016; 18: 1455-1490